CWM
CGTX icon

Castle Wealth Management’s Cognition Therapeutics CGTX Stock Holding History

Castle Wealth Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44,005
Closed -$59.4K – 133
2025
Q4 		$59.4K Hold
44,005
– – 0.02% 130
2025
Q3 		$59.4K Hold
44,005
– – 0.02% 128
2025
Q2 		$13.6K Buy
44,005
+625
+1% +$211 0.01% 122
2025
Q1 		$18.3K Hold
43,380
– – 0.01% 126
2024
Q4 		$30.4K Hold
43,380
– – 0.01% 117
2024
Q3 		$20.3K Hold
43,380
– – 0.01% 121
2024
Q2 		$72K Hold
43,380
– – 0.03% 116
2024
Q1 		$79K Hold
43,380
– – 0.04% 118
2023
Q4 		$80.3K Hold
43,380
– – 0.05% 116
2023
Q3 		$62.5K Hold
43,380
– – 0.04% 100
2023
Q2 		$79.4K Hold
43,380
– – 0.06% 109
2023
Q1 		$85.9K Hold
43,380
– – 0.07% 105
2022
Q4 		$91.1K Hold
43,380
– – 0.06% 108
2022
Q3 		$82K Hold
43,380
– – 0.05% 159
2022
Q2 		$92K Buy
+43,380
New +$112K 0.05% 153

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Castle Wealth Management's CGTX Position: Q1 2026 in Review

Castle Wealth Management sold out of Cognition Therapeutics (CGTX) in Q1 2026, closing a stake of 44,005 shares — an estimated $59.4K sold.

Castle Wealth Management first reported a position in CGTX in Q2 2022 and held it in 15 quarters. The position peaked at $92K in Q2 2022. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Castle Wealth Management reported no remaining Cognition Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Castle Wealth Management sold 44,005 Cognition Therapeutics shares in Q1 2026, an estimated $59.4K.
  • Castle Wealth Management first reported a position in Cognition Therapeutics in Q2 2022 and held it in 15 quarters.
  • Castle Wealth Management's Cognition Therapeutics position peaked at $92K in Q2 2022.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Castle Wealth Management's 13F filing for Q1 2026, filed 1 May 2026.